Published in Ther Clin Risk Manag on June 24, 2010
Elevated soluble Flt1 inhibits endothelial repair in PR3-ANCA-associated vasculitis. J Am Soc Nephrol (2011) 1.50
Complications of long-term therapy for ANCA-associated systemic vasculitis. Nat Rev Nephrol (2012) 0.86
Necrotizing and crescentic glomerulonephritis presenting with preserved renal function in patients with underlying multisystem autoimmune disease: a retrospective case series. Rheumatology (Oxford) (2014) 0.80
A physician survey reveals differences in management of idiopathic pulmonary hemosiderosis. Orphanet J Rare Dis (2015) 0.78
Fatal pulmonary complication during induction therapy in a patient with ANCA-associated vasculitis. Acta Med Litu (2016) 0.75
Familial vasculitides: granulomatosis with polyangitis and microscopic polyangitis in two brothers with differing anti-neutrophil cytoplasm antibody specificity. Clin Kidney J (2016) 0.75
Issues in trial design for ANCA-associated and large-vessel vasculitis. Nat Rev Rheumatol (2014) 0.75
Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum (1994) 14.16
Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med (1992) 13.29
Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med (1983) 8.26
A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med (2003) 7.30
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med (2009) 6.61
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature (2000) 6.54
Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol (2007) 6.13
Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med (2008) 5.94
Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest (2002) 5.42
Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J (1958) 5.38
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum (2003) 5.29
Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med (2005) 5.17
EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis (2008) 4.88
Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int (1998) 4.31
Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2005) 4.21
Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med (1996) 4.18
Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med (2008) 3.87
Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med (2008) 3.66
Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med (2005) 3.18
APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med (1998) 3.17
Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum (2008) 2.92
Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med (2003) 2.85
Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum (2008) 2.63
Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med (1994) 2.62
A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation (1996) 2.61
Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med (1996) 2.61
Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol (2007) 2.41
Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis (2003) 2.40
Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum (1997) 2.31
G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med (2003) 2.31
Relapses in Wegener's granulomatosis: the role of infection. Br Med J (1980) 2.29
Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum (2006) 2.14
Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet (1990) 2.12
Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum (2000) 2.12
Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis (2008) 2.12
Prominence of cell-mediated immunity effectors in "pauci-immune" glomerulonephritis. J Am Soc Nephrol (1999) 2.11
Interleukin-8: A pathogenetic role in antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. Kidney Int (1999) 2.10
The IL-23/Th17 axis contributes to renal injury in experimental glomerulonephritis. J Am Soc Nephrol (2009) 2.06
Th17 cells promote autoimmune anti-myeloperoxidase glomerulonephritis. J Am Soc Nephrol (2010) 2.03
Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol (2004) 1.99
The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol (2005) 1.97
Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) (2007) 1.95
Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood (2004) 1.91
Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation (1997) 1.90
Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood (2005) 1.86
Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA): a Fc gamma RII-dependent process. Clin Exp Immunol (1994) 1.85
Leukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritis. Kidney Int (2007) 1.77
A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2009) 1.74
Neutrophil priming and apoptosis in anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Kidney Int (2001) 1.67
Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. QJM (1996) 1.66
Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int (2007) 1.64
Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum (2008) 1.59
Th1 and Th17 cells induce proliferative glomerulonephritis. J Am Soc Nephrol (2009) 1.55
Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. Nephrol Dial Transplant (2010) 1.46
Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol (1998) 1.44
Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum (2008) 1.41
Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis. J Am Soc Nephrol (2002) 1.41
Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol (2004) 1.39
15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol (2003) 1.32
Monocyte activation in patients with Wegener's granulomatosis. Ann Rheum Dis (1999) 1.31
Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol (2001) 1.30
Epidemiology of Wegener's granulomatosis: Lessons from descriptive studies and analyses of genetic and environmental risk determinants. Clin Exp Rheumatol (2006) 1.26
Treatment of rolling neutrophils with antineutrophil cytoplasmic antibodies causes conversion to firm integrin-mediated adhesion. Arthritis Rheum (2000) 1.26
Antineutrophil cytoplasmic antibodies induce reactive oxygen-dependent dysregulation of primed neutrophil apoptosis and clearance by macrophages. Am J Pathol (2000) 1.24
Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant (2007) 1.24
Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int (2005) 1.18
Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis. Kidney Int (2003) 1.17
Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int (2004) 1.14
Activation of the G(i) heterotrimeric G protein by ANCA IgG F(ab')2 fragments is necessary but not sufficient to stimulate the recruitment of those downstream mediators used by intact ANCA IgG. J Am Soc Nephrol (2003) 1.14
High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum (2002) 1.07
Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis (2007) 1.06
T cell responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitis. Clin Exp Immunol (1996) 1.05
Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med (2003) 1.03
Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol (1996) 1.02
Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin Investig Drugs (2009) 1.02
BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun (2005) 1.02
Wegener's granulomatosis: antiproteinase 3 antibodies induce monocyte cytokine and prostanoid release-role of autocrine cell activation. J Leukoc Biol (2002) 1.02
Contrasting genetic association of IL2RA with SLE and ANCA-associated vasculitis. BMC Med Genet (2009) 1.01
Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum (2004) 1.01
Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. Rheumatology (Oxford) (2001) 1.00
Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's Granulomatosis Classification Criteria Cohort. Am J Med (1996) 1.00
Trial watch: BLYS-targeted antibody shows promise in Phase III SLE trial. Nat Rev Drug Discov (2009) 0.98
A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis. J Am Soc Nephrol (2009) 0.90
Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis. BMC Med Genet (2009) 0.90
Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthritis Rheum (1994) 0.90
Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis. J Clin Pharmacol (2008) 0.88
Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics. Mod Rheumatol (2009) 0.88
Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis. Nephrol Dial Transplant (1998) 0.87
European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. European Community Study Group on Clinical Trials in Systemic Vasculitis ECSYSVASTRIAL. Clin Exp Immunol (1995) 0.87
Current knowledge on cellular interactions in the WG-granuloma. Clin Exp Rheumatol (2007) 0.82
Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum (1997) 0.81
Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study. Br J Rheumatol (1996) 0.77
Tacrolimus as a reinforcement therapy for a patient with MPO-ANCA-associated diffuse alveolar hemorrhage. Clin Rheumatol (2006) 0.76
ANCA-associated vasculitis: from bench research to novel treatments. Nat Rev Nephrol (2009) 0.76
Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature (2006) 9.30
Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med (2012) 6.93
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med (2009) 6.61
Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol (2007) 6.13
FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat Genet (2007) 5.93
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med (2003) 4.20
Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet (2010) 3.74
Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol (2010) 3.48
Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis (2003) 2.40
Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis. Nephrol Dial Transplant (2011) 2.03
Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome. Stem Cells (2006) 1.90
Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood (2005) 1.86
Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int (2004) 1.85
Enzyme-linked immunosorbent spot assay analysis of peripheral blood lymphocyte reactivity to donor HLA-DR peptides: potential novel assay for prediction of outcomes for renal transplant recipients. J Am Soc Nephrol (2002) 1.81
Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) (2011) 1.79
Regulatory functions of CD8+CD28- T cells in an autoimmune disease model. J Clin Invest (2003) 1.76
A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2009) 1.74
The changing profile of acute tubulointerstitial nephritis. Nephrol Dial Transplant (2004) 1.73
Interferon-beta reduces proteinuria in experimental glomerulonephritis. J Am Soc Nephrol (2007) 1.63
Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum (2009) 1.59
Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J Immunol (2005) 1.58
Elevated soluble Flt1 inhibits endothelial repair in PR3-ANCA-associated vasculitis. J Am Soc Nephrol (2011) 1.50
Effect of L-carnitine administration on erythrocyte survival in haemodialysis patients. Nephrol Dial Transplant (2006) 1.46
Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. Nephrol Dial Transplant (2010) 1.46
Goodpasture's disease in the absence of circulating anti-glomerular basement membrane antibodies as detected by standard techniques. Am J Kidney Dis (2002) 1.42
Drug insight: rituximab in renal disease and transplantation. Nat Clin Pract Nephrol (2006) 1.41
Non-hepatitis virus associated mixed essential cryoglobulinemia. Kidney Int (2009) 1.40
The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol (2002) 1.38
Jund is a determinant of macrophage activation and is associated with glomerulonephritis susceptibility. Nat Genet (2008) 1.31
The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. J Clin Invest (2003) 1.26
Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. Kidney Int (2011) 1.24
Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy. Cytokine (2009) 1.23
Experimental autoimmune vasculitis: an animal model of anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis. Am J Pathol (2009) 1.21
Crescentic glomerulonephritis: new aspects of pathogenesis. Semin Nephrol (2011) 1.18
Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture's (anti-GBM) disease. Kidney Int (2003) 1.15
Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study. Rheumatology (Oxford) (2011) 1.12
New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs. Ann Surg (2002) 1.12
Physiological mechanisms of regulating alloimmunity: cytokines, CTLA-4, CD25+ cells, and the alloreactive T cell clone size. J Immunol (2002) 1.12
Anti-neutrophil cytoplasmic antibodies stimulate release of neutrophil microparticles. J Am Soc Nephrol (2011) 1.11
Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis. J Am Soc Nephrol (2007) 1.10
Revisiting ANCA-associated vasculitis in systemic sclerosis: clinical, serological and immunogenetic factors. Rheumatology (Oxford) (2013) 1.10
Therapeutic effect of anti-TNF-alpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J Am Soc Nephrol (2005) 1.09
P2X7 deficiency attenuates renal injury in experimental glomerulonephritis. J Am Soc Nephrol (2009) 1.08
Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int (2005) 1.07
Genes expressed by both mesangial cells and bone marrow-derived cells underlie genetic susceptibility to crescentic glomerulonephritis in the rat. J Am Soc Nephrol (2007) 1.07
Rituximab in refractory ophthalmic Wegener's granulomatosis: PR3 titers may predict relapse, but repeat treatment can be effective. Ophthalmology (2011) 1.07
Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. Nephrol Dial Transplant (2004) 1.07
Increased expression of the pro-apoptotic ATP-sensitive P2X7 receptor in experimental and human glomerulonephritis. Nephrol Dial Transplant (2006) 1.06
CD70 signaling is critical for CD28-independent CD8+ T cell-mediated alloimmune responses in vivo. J Immunol (2005) 1.06
Membranous glomerulonephritis associated with follicular B-cell lymphoma and subepithelial deposition of IgG1-kappa paraprotein. Nephron Clin Pract (2003) 1.05
Diffuse alveolar haemorrhage in ANCA-associated vasculitis. Intern Med (2013) 1.05
Intravenous cyclophosphamide and plasmapheresis in dialysis-dependent ANCA-associated vasculitis. Clin J Am Soc Nephrol (2012) 1.05
The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo. J Immunol (2003) 1.02
Inhibition of p38 mitogen-activated protein kinase is effective in the treatment of experimental crescentic glomerulonephritis and suppresses monocyte chemoattractant protein-1 but not IL-1beta or IL-6. J Am Soc Nephrol (2007) 1.01
Regulation of myeloperoxidase-specific T cell responses during disease remission in antineutrophil cytoplasmic antibody-associated vasculitis: the role of Treg cells and tryptophan degradation. Arthritis Rheum (2010) 1.00
Anti-CD8 monoclonal antibody therapy is effective in the prevention and treatment of experimental autoimmune glomerulonephritis. J Am Soc Nephrol (2002) 1.00
Leptin-deficient mice are protected from accelerated nephrotoxic nephritis. Am J Pathol (2004) 0.99
DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am J Kidney Dis (2004) 0.99
Genetic loci modulate macrophage activity and glomerular damage in experimental glomerulonephritis. J Am Soc Nephrol (2010) 0.99
New TCR transgenic model for tracking allospecific CD4 T-cell activation and tolerance in vivo. Am J Transplant (2003) 0.97
Shining a LAMP on pauci-immune focal segmental glomerulonephritis. Kidney Int (2009) 0.96
Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis. Kidney Int (2013) 0.96
The evolution of crescentic nephritis and alveolar haemorrhage following induction of autoimmunity to glomerular basement membrane in an experimental model of Goodpasture's disease. J Pathol (2003) 0.95
Protein load impairs factor H binding promoting complement-dependent dysfunction of proximal tubular cells. Kidney Int (2009) 0.93
Nasal administration of recombinant rat alpha3(IV)NC1 prevents the development of experimental autoimmune glomerulonephritis in the WKY rat. J Am Soc Nephrol (2005) 0.93
Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. Clin J Am Soc Nephrol (2010) 0.93
P2X7 receptor-mediated Nlrp3-inflammasome activation is a genetic determinant of macrophage-dependent crescentic glomerulonephritis. J Leukoc Biol (2012) 0.92
Commentary: Iloprost for cholesterol emboli syndrome. BMJ (2002) 0.92
Glomerulonephritis due to antineutrophil cytoplasm antibody-associated vasculitis: an update on approaches to management. Nephrology (Carlton) (2005) 0.92
Pulmonary-renal syndrome: a life threatening but treatable condition. Postgrad Med J (2013) 0.91
Proteinase-3 antineutrophil cytoplasm antibody positivity in patients without primary systemic vasculitis. J Clin Rheumatol (2012) 0.90
Interstitial fibrosis is associated with increased COL1A2 transcription in AA-injured renal tubular epithelial cells in vivo. Matrix Biol (2011) 0.90
A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis. J Am Soc Nephrol (2009) 0.90
Treatment with an antibody to VLA-1 integrin reduces glomerular and tubulointerstitial scarring in a rat model of crescentic glomerulonephritis. Am J Pathol (2002) 0.90
Rapidly progressive glomerulonephritis: current and evolving treatment strategies. J Nephrol (2004) 0.90
Lymphocytes from P2X7-deficient mice exhibit enhanced P2X7 responses. J Leukoc Biol (2009) 0.89
Mucormycosis may mimic disease relapse in Wegener's granulomatosis. J Rheumatol (2010) 0.89
Mechanisms of tolerance induced by donor-specific transfusion and ICOS-B7h blockade in a model of CD4+ T-cell-mediated allograft rejection. Am J Transplant (2005) 0.89
Renal transplantation in systemic vasculitis: when is it safe? Nephrol Dial Transplant (2009) 0.89
Delayed hepato-spleno-renal bypass for renal salvage following malposition of an infrarenal aortic stent-graft. J Endovasc Ther (2010) 0.88
Long- term outcome of paediatric patients with ANCA vasculitis. Pediatr Rheumatol Online J (2011) 0.87
Mucosal tolerance induced by an immunodominant peptide from rat alpha3(IV)NC1 in established experimental autoimmune glomerulonephritis. Am J Pathol (2009) 0.87
Pharmacological use of L-carnitine in uremic anemia: has its full potential been exploited? Pharmacol Res (2010) 0.87
A nephritogenic peptide induces intermolecular epitope spreading on collagen IV in experimental autoimmune glomerulonephritis. J Am Soc Nephrol (2006) 0.87